Anaveon Announces Presentation of Positive ANV600 Clinical Data at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio

Contributed by: GlobeNewswire

Tags

Clinical Data

More Like This

Anaveon appoints Biotech Leader Thaminda Ramanayake as Chief Executive Officer

New and Exciting Clinical Data on Evaxion’s AI-Immunology™-Based Personalized Cancer Vaccines to be Presented

Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak

Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

Bionoxx to Highlight Innovative Strategy for Addressing Immune-Related Diseases at 2024 BIO International Conference

Business Wire logo

Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress

iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress